Sanaria Inc.

USA As Represented by Secretary of the Navy

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The Johns Hopkins University

The Rockefeller University

Protein Potential, LLC

Other

Glaxosmithkline Biologicals Sa

Antigen Discovery, Inc.

Stephen L Hoffman

B Kim Lee Sim

Richard E Stafford

Minglin Li

Yupin Charoenvit

Abraham G Eappen

Sumana Chakravarty

Dennis J Kopecko

Robert Seder

Yun Wu

Russell H Taylor

Iulian Ioan Iordachita

Moriya Tsuji

Gregory Chirikjian

Denise L Doolan

Neville Kisalu

Azza Idris

Barbara Flynn

Richard C Hedstrom

Trevor R Jones

Thomas C Luke

Philip L Felgner

Joseph D Cohen

Balazs Peter Vagvolgyi

Jin Seob Kim

Martha Sedegah

Kevin R Porter

Tadeusz Kochel

Joshua D Davis

Can Kocabalkanli

Curtis G Hayes

Socrates Herrera

Henry Phalen

Hongtao Wu

Mengdi Xu

Shengnan Lu

Joseph J Campo, Jr

Michael Aaron Pozin

Brian K Chirikjian

Ting Da

John S Chirikjian

Kanakatte Raviprakash

Richard L Beaudoin

Amanda Canezin

Richard Hedstrom

Srisin Khusmith

Mariah Schrum

Judith E Epstein

William O Rogers, Iv

Ruobing Wang

Gary Todd Brice

Kim Lee Sim

Michelle Laskowski

Myriam Arevalo

Disclosed is the attenuatedvaccine Ty21a utilized as a vector forand/or enterotoxogenicgenes stably integrated in the Ty21a chromosome. These genes include a heterologousO-antigen biosynthetic gene region that comprises the wzz gene and expressesform 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.

Live attenuated oral vaccine against shigellosis and typhoid fever

The application is directed to in vitro-rearedsporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectioussporozoites (SPZ) of human host range, particularly, and, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.

Infectious plasmodium sporozoites grown in vitro

Infectioussporozoites grown in vitro

Antibodies and antigen binding fragments that specifically bind tocircumsporozoite protein and neutralizeare disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit ainfection.

Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use

Systems and methods for providing a combined mosquito staging and dissection system are disclosed. The system can include a mosquito staging subsystem; a robotic pick-and-place station; and a dissection, extrusion, collection, and disposal subsystem. The subsystems can include one or more stations to provide orientation, decapitation, extrusion of salivary glands, and disposal of carcasses of the mosquitoes. The resident live sporozoites from the salivary glands can be used to produceSPZ-based vaccines.

Apparatus and method of use for an automated mosquito salivary gland extraction device

Live attenuated oral vaccine against ETEC and typhoid fever

A device and method of use for augmenting the extraction of salivary glands from-infected mosquitoes, where the sporozoite stage ofprimarily resides. Sporozoites are useful for research as well as for the immunogen in whole parasite vaccines for the prevention of malaria. The device and methods of use disclosed herein greatly increase the rate at which sporozoites can be harvested.

Mosquito salivary gland extraction device and methods of use

Disclosed are substantially purifiedsporozoites and preparations ofsporozoites substantially separated from attendant non-sporozoite material, where the preparations ofsporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purifiedsporozoites are likewise provided. Methods of purifying preparations ofsporozoites are also provided.

Purified plasmodium and vaccine compositions

Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected againstcaused malaria. Such methods are particularly useful for determining not only the protective efficacy of Pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects. Also disclosed herein are subunit vaccines comprising at least one Pf immunologic determinant for protection against-caused malaria.

Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines

The application is directed to in-vitro-rearedsporozoites of human host range wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same. Provided herein are in vitro-reared infectioussporozoites (SPZ) of human host range, particularly, and, wherein sporogony from gametocyte stage to sporozoite stage is external to mosquitoes, and methods of producing the same.

Disclosed herein are pharmaceutical compositions comprisingsporozoite-stage parasites and compatible glycolipid adjuvants useful in vaccines for preventing or reducing the risk of malaria. In particular, human host rangeand analogues of &#x3b1;-galactosylceramide (&#x3b1;-GalCer), a ligand for natural killer T (NKT) cells, are combined in pharmaceutical compositions, which are useful as vaccines against malaria. Methods of use are also provided.

[object Object]

Growing community of inventors

Gaithersburg, MD, United States of America

Stephen L Hoffman